Srk-015
Anti-myostatin
Scholar Rock, Inc.Phase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Anti-myostatin cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nusinersen Scholar Rock, Inc. | Phase 2 | CCC |
Risdiplam Scholar Rock, Inc. | Phase 2 | CCC |
Same molecule, other indications
Srk-015 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →